These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34524728)

  • 1. A Step toward NRF2-DNA Interaction Inhibitors by Fragment-Based NMR Methods.
    Brüschweiler S; Fuchs JE; Bader G; McConnell DB; Konrat R; Mayer M
    ChemMedChem; 2021 Dec; 16(23):3576-3587. PubMed ID: 34524728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning.
    Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K
    Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
    Abed DA; Lee S; Hu L
    Bioorg Med Chem; 2020 Mar; 28(6):115343. PubMed ID: 32046917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
    Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
    J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR Fragment-Based Screening against Tandem RNA Recognition Motifs of TDP-43.
    Nshogoza G; Liu Y; Gao J; Liu M; Moududee SA; Ma R; Li F; Zhang J; Wu J; Shi Y; Ruan K
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
    Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
    Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
    Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
    J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy.
    Lin H; Qiao Y; Yang H; Nan Q; Qu W; Feng F; Liu W; Chen Y; Sun H
    Future Med Chem; 2020 Feb; 12(3):243-267. PubMed ID: 31950858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.
    Simov V; Altman MD; Bianchi E; DelRizzo S; DiNunzio EN; Feng G; Goldenblatt P; Ingenito R; Johnson SA; Mansueto MS; Mayhood T; Mortison JD; Serebrov V; Sondey C; Sriraman V; Tucker TJ; Walji A; Wan H; Yue Y; Stoeck A; DiMauro EF
    Eur J Med Chem; 2021 Nov; 224():113686. PubMed ID: 34303079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
    Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
    Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
    Londhe AM; Gadhe CG; Lim SM; Pae AN
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
    Jiang ZY; Lu MC; You QD
    J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nrf2, the Major Regulator of the Cellular Oxidative Stress Response, is Partially Disordered.
    Karunatilleke NC; Fast CS; Ngo V; Brickenden A; Duennwald ML; Konermann L; Choy WY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of the interactions between the disordered Neh4 and Neh5 domains of Nrf2 and CBP/p300 in oxidative stress response.
    Karunatilleke NC; Brickenden A; Choy WY
    Protein Sci; 2024 Sep; 33(9):e5137. PubMed ID: 39150085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Peptide Inhibitors of the Keap1-Nrf2 Protein-Protein Interaction Incorporating Unnatural Amino Acids.
    Georgakopoulos ND; Talapatra SK; Gatliff J; Kozielski F; Wells G
    Chembiochem; 2018 Sep; 19(17):1810-1816. PubMed ID: 29927029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico Evidence for Binding of Pentacyclic Triterpenoids to Keap1-Nrf2 Protein-Protein Binding Site.
    Kamble SM; Patel HM; Goyal SN; Noolvi MN; Mahajan UB; Ojha S; Patil CR
    Comb Chem High Throughput Screen; 2017; 20(3):215-234. PubMed ID: 28024463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.
    Ziarek JJ; Liu Y; Smith E; Zhang G; Peterson FC; Chen J; Yu Y; Chen Y; Volkman BF; Li R
    Curr Top Med Chem; 2012; 12(24):2727-40. PubMed ID: 23368099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based Methods.
    Kessler D; Mayer M; Zahn SK; Zeeb M; Wöhrle S; Bergner A; Bruchhaus J; Ciftci T; Dahmann G; Dettling M; Döbel S; Fuchs JE; Geist L; Hela W; Kofink C; Kousek R; Moser F; Puchner T; Rumpel K; Scharnweber M; Werni P; Wolkerstorfer B; Breitsprecher D; Baaske P; Pearson M; McConnell DB; Böttcher J
    ChemMedChem; 2021 May; 16(9):1420-1424. PubMed ID: 33275320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.